Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

Научно-практическая ревматология

A. M. Lila¹  B. S. Belov²  A. I. Zagrebneva³  A. E. Karateev⁴  A. A. Baranov⁵  D. I. Abdulganieva⁵  E. L. Nasonov⁵  O. A. Nikitinskaya⁵  V. I. Mazurov⁵  T. V. Dubinina⁵  S. V. Moiseev⁶ 

[1] I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University);Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation;Kazan State Medical University;North-Western State Medical University named after I.I. Mechnikov;V.A. Nasonova Research Institute of Rheumatology;Yaroslavl State Medical University of the Ministry of Health of Russia;

关键词: covid-19;    immune-mediated rheumatic diseases;    dmards;    biologics;    vaccination;   

DOI  :  10.47360/1995-4484-2021-239-254

来源: DOAJ

【 摘 要 】

In mid-2021, the SARS-CoV-2 (Severe Acute Respiratory coronavirus 2) infection, which caused the coronavirus disease (COVID-19) pandemic, affected more than 157 million people in all regions of the world and led to more than 3.2 million deaths. It is assumed that elderly age, uncontrolled inflammation, anti-inflammatory therapy, comorbid pathology, genetic and other factors can potentially lead to an increase in “sensitivity” to viral and bacterial infections, including SARS-CoV-2. The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.

【 授权许可】

Unknown